Benitec Biopharma Files Q3 10-Q Report
Ticker: BNTC · Form: 10-Q · Filed: May 14, 2025 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biopharma
TL;DR
Benitec Biopharma dropped its Q3 10-Q. Check financials.
AI Summary
Benitec Biopharma Inc. filed its Q3 10-Q report for the period ending March 31, 2025. The filing details financial information and operational updates for the company. Specific financial figures and operational highlights are not detailed in the provided header information, but the report covers the third quarter of their fiscal year.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Benitec Biopharma, crucial for evaluating the company's trajectory.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Benitec Biopharma operates in a highly regulated and research-intensive industry with inherent risks related to drug development and market approval.
Key Numbers
- Q3 — Quarter (Reporting period for the 10-Q)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Filer of the 10-Q report
- 2025-03-31 (date) — End of the reporting period
- 20250514 (date) — Filing date
FAQ
What were Benitec Biopharma's total revenues for the third quarter ending March 31, 2025?
The provided header information does not contain specific revenue figures for the quarter ending March 31, 2025.
What was Benitec Biopharma's net income or loss for the third quarter ending March 31, 2025?
Specific net income or loss details for the quarter ending March 31, 2025, are not available in the header information.
What are the key research and development activities highlighted in this 10-Q filing?
The header information does not detail specific research and development activities for the period ending March 31, 2025.
Did Benitec Biopharma announce any significant corporate events or partnerships in the period leading up to March 31, 2025?
The provided header information does not list any specific corporate events or partnerships for the period ending March 31, 2025.
What is the company's cash and cash equivalents balance as of March 31, 2025?
The header information for this 10-Q filing does not include the company's cash and cash equivalents balance as of March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Benitec Biopharma Inc. (BNTC).